Robert Busch, MD: EMPEROR-Reduced Topline Data and SGLT2 Class

August 1, 2020

A practicing endocrinologist discusses his reaction to topline results from EMPEROR-REDUCED and what he hopes to see in the presentation at ESC 2020.

Hear from Robert Busch, MD, as he offers his thoughts on the topline results of EMPEROR-REDUCED. Released on June 30, topline results of the study indicate use of empagliflozin (Jardiance) was associated with a reduction in the composite endpoint of death and worsening heart failure.

Scheduled to be presented almost one year after the results of DAPA-HF, full results of EMPEROR-REDUCED could definitively prove the benefit seen on heart failure is truly a class effect of SGLT2 inhibitors.